Skip to content
Start consultationStart
Weight loss · Florence

Victoza in Florence, online

An EU-licensed doctor reviews your case and, if eligible, issues an electronic prescription you can collect at a pharmacy in Florence.

From€25/ 28 days

Consultation price. The medicine is paid at your pharmacy.

  • Prescription only, if a doctor approves
  • Doctor-reviewed renewals
  • Full refund if not approved
Start consultation
Victoza

Licensed EU doctors

Every case read by a registered doctor.

Reply in under 2 hours

On average, in writing, no video call.

Pay only if approved

Not approved? Refunded in full, automatically.

Rated excellent on Trustpilot

4.8 from 540+ independent reviews.

Valid across the EU

E-prescription accepted at EU pharmacies.

Local facts

Victoza consultations in Florence

Available toResidents of Italy
LanguagesSpanish and English
Doctor replyUnder 2 hours on average
Collected atPharmacies in Italy · e-prescription (PDF)
About the medicine

What it is and how it works

Liraglutide is a GLP-1 receptor agonist given as a daily subcutaneous injection. It was one of the first in its class approved in Europe for weight management in adults with obesity, or overweight with comorbidities.

Compared with weekly GLP-1s, its daily dosing can be useful when flexibility of adjustment matters or when a semaglutide hasn't been tolerated. The doctor weighs this up in your consultation. Two GLP-1 agonists are never combined.

Who it is for

  • Adults with a BMI of 30 or more, or 27 or more plus a weight-related illness.
  • One injection every day, at any time, built up from 0.6 mg to 3.0 mg.

Safety summary

Nausea and diarrhoea are very common; severe stomach pain can signal pancreatitis.

Read the safety summary
Pricing

One consultation, one clear price

You pay for the doctor's consultation. If a prescription is issued, the medicine is paid at your own pharmacy.

  • Consultation reviewed by an EU-licensed doctor
  • Private follow-up in the in-app chat
  • Full refund if the doctor does not approve
Plan or one-off

Weight loss

Monthly planCancel anytime€25/ 28 daysOne-off28-day treatment€35once
  • First consultation included
  • Renewals reviewed by your doctor
  • Ongoing care in your private chat
  • Cancel anytime
Start consultation

Full refund if a review is not approved

FAQs

Your questions answered

Victoza16 questions
What is liraglutide and how is it administered?
It is a GLP-1 receptor agonist given as a daily subcutaneous injection. It was one of the first in its class approved in Europe for weight management in adults with obesity or overweight with comorbidities.
It depends on the case. Semaglutide generally shows larger average weight loss and is given weekly; liraglutide is daily and can be useful when flexibility is needed or a semaglutide has not been tolerated. The doctor weighs this up in your consultation.
More questions
Mild nausea, early fullness and occasional constipation, especially when escalating the dose. They are usually transient. Severe or persistent abdominal pain requires contacting the doctor via the private chat.
Two GLP-1 agonists are not combined. It is compatible with a structured nutrition and activity plan. The doctor reviews all your current medication before prescribing.
The active ingredient is the same, but the licence and the dose are not. Both contain liraglutide. Saxenda was authorised in the EU on 23 March 2015 for weight management, and is built up to a maintenance dose of 3.0 mg once daily. Victoza was authorised on 30 June 2009 for type 2 diabetes, where the maximum daily dose is 1.8 mg. Because the licensed indications differ, a prescriber writes for the product that matches the reason for treatment, and the two are not interchangeable.
Because it clears from the body much faster. Liraglutide has an elimination half-life of about 13 hours, so a dose does not last a week and has to be repeated every 24 hours to keep a steady level. Semaglutide and tirzepatide are engineered to stay in the blood far longer, which is why they are given once weekly. The practical difference is 365 injections a year rather than 52. That matters for some people and not for others, and it is worth raising with the prescriber before starting.
Treatment is stopped. The EU product information says liraglutide should be discontinued after 12 weeks on the 3.0 mg daily dose if a patient has not lost at least 5% of their starting body weight. The rule exists because the trials showed early response predicts later response: of the people who had lost less than 5% at that point, 93.4% did not go on to reach a 10% loss at one year. Your prescriber reviews your weight at the 12-week mark and decides whether continuing makes sense.
Write to your doctor in the private chat in your account: describe what you notice and when it started. The doctor can adjust the plan, pause it or suggest another option. If you have severe symptoms such as difficulty breathing, swelling of the face or chest pain, call 112 or go to an emergency department straight away.
It depends on what you take. List every medicine, supplement and herbal product in the questionnaire, including ones you use only occasionally. The doctor checks for interactions before prescribing, and your pharmacist checks again when you collect Victoza.
The doctor can consider another weight-management medicine authorised in the EU, or a plan built on nutrition and activity alone. Some people are better served by an in-person obesity clinic or by their own doctor, and the doctor explains why when that is the case.
Before each renewal the doctor reviews your weight, side effects and how you feel, and decides whether to continue, change the dose or stop. Changes are never automatic. You can also write in the private chat between reviews.
Yes. Hi-Doctor runs 100 % online across the EU, so if you live in Florence you can fill in the questionnaire and receive the medical review without travelling. The electronic prescription issued by the licensed doctor is valid in any EU pharmacy under Directive 2011/24/EU; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.
Adults with BMI ≥ 30, or ≥ 27 with comorbidities (hypertension, type-2 diabetes, dyslipidaemia). The doctor reviews your history, current medication and goals before proposing any treatment. It is not a cosmetic programme.
The private electronic prescription (Receta Médica Privada Electrónica) is issued by a licensed doctor in Spain. It is a PDF carrying every field required by EU Directive 2011/24/EU (patient, prescriber with country of registration, active ingredient, dose), which makes it legally recognised across all 27 EU member states. In Spanish pharmacies it is dispensed from the QR; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.
1) Fill in an online medical questionnaire in about 4 minutes. 2) The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health is €35 per consultation and a skin consultation is €40. 3) An EU-licensed doctor reviews your case and, if appropriate, issues an electronic prescription. 4) Collect it at any EU pharmacy. If the review is not approved, the applicable fee is refunded in full.
The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; a one-off sexual-health consultation is €35 and a skin consultation covering acne, rosacea, melasma and ageing skin is €40. Each includes a licensed doctor's review and an electronic prescription if approved. If the review is not approved, the applicable fee is refunded in full. Medication is paid for separately at the pharmacy at the price it sets.
Behind the scenes

How your doctor decides

Your answers

A licensed doctor reads your full questionnaire.

Medical judgement

The decision is clinical, never an algorithm.

Clear outcome

Approved with an e-prescription, or refunded in full.

Also for Weight loss

Related medicines

Medicine information and safety

How does Victoza work?

Copies one gut hormone. Liraglutide is a copy of a natural gut hormone called GLP-1, which the body releases after eating. The EU product information describes it as an acylated human GLP-1 analogue with 97% amino acid sequence homology to the human hormone, and it binds to and activates the GLP-1 receptor.

Raises fullness, lowers hunger. GLP-1 receptors also sit in brain regions that regulate appetite. The product information reports that liraglutide increases feelings of fullness and satiety while lowering hunger and prospective food consumption, so people eat less. It does not increase energy expenditure compared with placebo.

Short-acting, so taken daily. Liraglutide has an elimination half-life of roughly 13 hours, which is why it is injected once every day rather than once a week like semaglutide or tirzepatide. It also raises insulin and lowers glucagon in a glucose-dependent way, and weight is lost mainly as fat mass.

How to use Victoza

Inject once every day. Liraglutide is injected once daily, at any time of day, with or without food. Unlike weekly injections it needs a dose every 24 hours, so it is easiest to pick a convenient time and keep to it.

Start low and build up. Treatment starts at 0.6 mg once daily and rises by 0.6 mg at intervals of at least a week, reaching the 3.0 mg maintenance dose in week 5. The slow climb is there to improve stomach and bowel tolerance.

Tummy, thigh or upper arm. The injection goes under the skin of the abdomen, the thigh or the upper arm. It must never be given into a vein or a muscle. Rotate the site each day to reduce the risk of amyloid deposits building up under the skin.

Check the pen before use. Look at the liquid before you inject. It should be clear and colourless, or almost colourless. With a new pen, do the flow check described in the instructions so you can see a drop appear at the needle tip before setting your dose.

Missed dose: the 12 hour rule. If you remember within 12 hours of your usual time, take the dose as soon as you can. If there is less than 12 hours until the next one, skip it and carry on as normal. Never take an extra dose.

Store pens in the fridge. Unused pens are kept in a refrigerator between 2 and 8 degrees Celsius, away from the freezer compartment, and must not be frozen. A pen in use can be stored below 30 degrees Celsius or refrigerated, and is discarded one month after first use.

Drink enough fluid. Nausea, vomiting and diarrhoea are common at the start and can leave you short of fluid. Dehydration has been linked to kidney impairment and acute kidney failure on GLP-1 medicines, so drink plenty and tell your doctor if you cannot keep fluids down.

Keep the diet and activity going. Liraglutide is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them. Every trial result quoted on this page comes from people doing both alongside the daily injection.

Common side effects

Stop and get urgent medical help if (seek medical help immediately): Severe and lasting pain in the stomach area that may reach through to your back, which can signal pancreatitis, Severe pain high in the tummy, usually worst on the right side under the ribs, which can signal gallstones or an inflamed gall bladder, Breathing problems, or swelling of the face, lips, tongue or throat, which can signal a severe allergic reaction, Vomiting or diarrhoea so severe or so lasting that you cannot keep fluids down, because dehydration can lead to kidney failure, Cold sweat, pale skin, shakiness, headache and confusion, if you also take insulin or a sulfonylurea for diabetes, A racing or pounding heartbeat while you are resting, which the prescriber needs to review, Severe stomach pain with bloating and no bowel movement, which can signal a blocked bowel

Very common (very common (≥1/10)): Feeling sick (nausea), most often while the dose is being increased, Being sick (vomiting), Diarrhoea, Constipation, Headache

Common (common (≥1/100 to <1/10)): Low blood sugar symptoms, self-reported and not confirmed by a blood glucose reading, in people without type 2 diabetes, Trouble sleeping, mainly during the first three months, Dizziness, A change in the sense of taste, Dry mouth, Indigestion, gastritis or acid reflux, Pain in the upper part of the tummy, Wind, burping or a bloated tummy, Gallstones, Rash, Injection site reactions, Weakness or tiredness, Raised lipase or amylase on blood tests

Uncommon (uncommon (≥1/1,000 to <1/100)): Dehydration, A faster heart rate (tachycardia), Pancreatitis, which is inflammation of the pancreas, Delayed stomach emptying, Inflammation of the gall bladder (cholecystitis), Nettle rash (urticaria), Generally feeling unwell

Rare (rare (≥1/10,000 to <1/1,000)): Anaphylactic reaction, a sudden and severe whole-body allergic reaction, Acute kidney failure, Kidney impairment

Frequency not known (frequency not known (cannot be estimated from the available data)): Intestinal obstruction, a blockage of the bowel, reported after the medicine went on the market, Cutaneous amyloidosis, a lumpy deposit that can build up under the skin at the injection site

Do not use Victoza if

  • You have ever had an allergic reaction to liraglutide or to any other ingredient in the pen. This is the only absolute contraindication in the EU product information.
  • You are pregnant, or you want to become pregnant. Liraglutide should not be used in pregnancy, and treatment is discontinued if pregnancy occurs.
  • You are breastfeeding. It is not known whether liraglutide passes into human milk, so it should not be used while breastfeeding.
  • You or a close relative have had medullary thyroid carcinoma, or you have multiple endocrine neoplasia syndrome type 2. US labelling makes this an outright contraindication; EU labelling advises caution in anyone with thyroid disease.
  • You have had pancreatitis. If pancreatitis is suspected liraglutide is stopped, and if it is confirmed it is not restarted.
  • You have gallstones or gall bladder disease. Weight-management trials found more gallstones and gall bladder inflammation on liraglutide than on placebo.
  • You have severe kidney impairment, including end-stage kidney disease, or severe liver impairment. Liraglutide is not recommended in these groups.
  • You have inflammatory bowel disease or diabetic gastroparesis. Experience is limited and the medicine is not recommended, because it causes stomach and bowel effects.
  • You already take another GLP-1 receptor agonist, or you would be using it as a replacement for insulin. Neither is allowed.
  • You have New York Heart Association class IV heart failure, or you are 75 years or older. There is no clinical experience in these groups, so use is not recommended.

Medicines and substances that interact

  • Insulin and sulfonylureas (for example gliclazide): Combined use in type 2 diabetes raises the risk of low blood sugar, sometimes severe. The prescriber may lower the insulin or sulfonylurea dose and asks for blood glucose self-monitoring.
  • Other GLP-1 receptor agonists: Two medicines acting on the same receptor add side effects without an established extra benefit. Liraglutide for weight management must not be combined with another GLP-1 receptor agonist.
  • Warfarin and other coumarin blood thinners: No interaction study was done, and a clinically relevant effect on warfarin cannot be excluded. The prescriber arranges more frequent INR checks when liraglutide is started.
  • Oral medicines in general: Liraglutide slightly delays stomach emptying, which can slow how fast a tablet is absorbed. Interaction studies showed no clinically relevant delay, so no dose change is required.
  • Paracetamol: Peak paracetamol level fell by 31% and was reached up to 15 minutes later; total exposure was unchanged. No dose adjustment is needed for paracetamol taken alongside liraglutide.
  • Combined oral contraceptives: Peak ethinylestradiol and levonorgestrel levels fell by 12% and 13%, with no relevant change in total exposure. The contraceptive effect is expected to be unaffected, so no change is required.
  • Atorvastatin, digoxin and lisinopril: Peak levels fell by 38%, 31% and 27% respectively, with only small changes in total exposure. No dose adjustment of any of these three is required based on those results.
  • General anaesthesia or deep sedation: Delayed stomach emptying can leave food in the stomach, and pulmonary aspiration has been reported. Tell the anaesthetic team you take liraglutide before any procedure needing anaesthesia or sedation.

References

  1. Saxenda (liraglutide): European public assessment report, medicine overview European Medicines Agency, 2015
  2. Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics European Medicines Agency, 2026
  3. Saxenda 6 mg/mL solution for injection in pre-filled pen: Summary of Product Characteristics electronic medicines compendium (emc), 2026
  4. Saxenda 6 mg/mL solution for injection in pre-filled pen: Patient Information Leaflet electronic medicines compendium (emc), 2026
  5. Liraglutide (Saxenda, Diavic, Zegluxen): NHS medicines A to Z NHS, 2026
  6. SCALE Obesity and Prediabetes: a randomized, controlled trial of 3.0 mg of liraglutide in weight management New England Journal of Medicine, 2015
  7. SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss International Journal of Obesity, 2013
  8. Victoza (liraglutide): European public assessment report, medicine overview European Medicines Agency, 2009
  9. Saxenda (liraglutide) injection: US prescribing information, boxed warning and contraindications DailyMed, US National Library of Medicine, 2026
  10. CIMA: Saxenda presentations, marketing and prescription status in Spain AEMPS (Spanish Agency of Medicines and Medical Devices), 2026
  11. Sozialgesetzbuch V § 34: medicines excluded from statutory health insurance, including those for weight regulation Bundesministerium der Justiz (gesetze-im-internet.de), 2026
  12. Liraglutide: preparaattekst and vergoeding conditions in the Netherlands Farmacotherapeutisch Kompas, Zorginstituut Nederland, 2026
  13. Liraglutide (Saxenda): health technology assessment and HSE reimbursement decision National Centre for Pharmacoeconomics (Ireland), 2023
  14. Rejestr Produktow Leczniczych: Saxenda registration record in Poland Centrum e-Zdrowia (Poland), 2026
  15. INFOMED: base de dados de medicamentos de uso humano INFARMED (Portugal), 2026
  16. STEP 1: Once-weekly semaglutide in adults with overweight or obesity New England Journal of Medicine, 2021
  17. SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity New England Journal of Medicine, 2022
  18. XENDOS: XENical in the prevention of Diabetes in Obese Subjects, a 4-year randomised study Diabetes Care, 2004
  19. Wegovy (semaglutide) solution for injection: Summary of Product Characteristics electronic medicines compendium (emc), 2026
  20. Xenical 120 mg hard capsules: Summary of Product Characteristics electronic medicines compendium (emc), 2026

Also available in

Semaglutide
Semaglutide
Ozempic
Ozempic
Wegovy
Wegovy
Online doctor by city

Also available in

RomeMilanNaplesTurinPalermoGenoaBolognaFlorenceBariCatania

Start your treatment journey

A doctor replies in under 2 hours on average.

Start consultationNo charge unless a doctor approves your treatment.
All content on this page has been medically reviewed by: Dr. Alejandro Infante, General medicine, on 27 July 2026. Registration: 080869277 View profile

Pay nothing if a doctor doesn't approve your treatment. Every consultation is fully refundable. How refunds work